Chief Scientific Officer & Executive Vice President – Product Development, Vectura

Dr Geraldine Venthoye is a member of Vectura’s executive leadership team and a board director of its subsidiary companies in Switzerland and Germany.
She leads the Pharmaceutical Development and Medical Device Development departments responsible for the strategic and technical advancement of the company’s products, development services and technology platforms.
Geraldine joined Vectura in June 2016 upon completion of the merger with Skyepharma PLC, where she had been executive vice president of pharmaceutical development since 2013, and head of the inhalation business unit since 2003. Geraldine previously held leadership and scientific roles in Nektar Therapeutics, Vandsons Research and Norton Healthcare.
During her 30 years of inhalation product research and development, she has worked on a range of inhalable generic and novel products, including Flutiform® pMDI, TOBI® DPI (anti-infective for cystic fibrosis), and biologic aerosol products using novel particle engineering to treat systemic diseases via the lung such as diabetes, osteoporosis and infertility.
Geraldine is a UK-registered pharmacist and holds a doctorate degree in pharmaceutics from the University of London. She completed her pre-registration clinical training at the Brompton Heart and Lung Hospital in London.


17 November 2020